JPMorgan analyst Sebastiano Petti lowered the firm's price target on Anterix to $50 from $67 and keeps an Overweight rating on the shares. The company's accelerator program remains oversubscribed, but investors are still awaiting new deal signings, the analyst tells investors in a research note. The firm says Anterix attributes the delay to the overall complexity of the deals and the risk management processes of the utilities involved. JPMorgan finds the stock "very attractive" at current levels.
